+441518081136Preliminary results of continuation maintenance treatment with pemetrexedin advanced non-squamous non-small cell lung cancer (NSCLC) patients after prior induction chemotherapy - single-arm phase II study
International Conference on Oncology and Cancer Therapeutics
October 30- November 01, 2017 | Chicago, USA
Nesreen M Sabry
Tanta University, Egypt
Posters & Accepted Abstracts : J Med Oncl Ther
Abstract:
Statement of the Problem: Lung cancer remains one of the leading causes of cancer-related death worldwide. Extending the duration of treatment with the initial platinum based chemotherapy beyond four to six cycles has been evaluated. The aim of this study is to investigate efficacy and toxicity of continuation maintenance treatment with pemetrexed (Alimta) in patients displaying disease control after four cycles of induction with cisplatin plus pemetrexed in advanced non squamous (NSCLC). Methodology & Theoretical Orientation: Between April 2013 and April 2015, 16 patients with pathologically proven stage III/IV, non-squamous NSCLC, in Clinical Oncology Department, Tanta University Hospital and Tanta Insurance Hospital who had received prior four cycles of induction with cisplatin (75mg/m2) plus pemetrexed (500mg/m2) every 21 days without disease progression were enrolled. Patients received continuation maintenance treatment with pemetrexed (500mg/m2 for every 21 days). The primary endpoints of the study were the overall survival and progression-free survival. Secondary end point was the safety profile. Finding: A total of 64 chemotherapy cycles of continuation maintenance pemetrexed were administered. Patients were treated with a median number of 4 cycles (range 2-30 cycles). Two patients received no more than 2 cycles due to rapid disease progression. The estimated median PFS and OS were 7.5 and 17 months, respectively. Treatment-related adverse events were manageable with only 1 patient (6.25%) suffered from Grade 3 anemia and another 1 patient (6.25%) suffered from Grade 4 neutropenia. All patients received full doses of pemetrexed throughout the study. There was no treatment-related death. Conclusion & Significance: Using the continuation maintenance regimen with pemetrexed preceded by four cycles of induction with cisplatin plus pemetrexed represents an obvious treatment advance with an acceptable clinical profile for patients with non-squamous NSCLC patients
PDF HTML